Jens D Bentzen1, Hanne Sand Hansen. 1. Department of Radiotherapy and Oncology, University Hospital in Herlev, 2730 Herlev, Denmark. jeben@herlevhosp.kbhamt.dk
Abstract
BACKGROUND: The aim of this phase II study was to evaluate the antitumor activity and toxicity of a non-platin-containing regimen with paclitaxel and capecitabine. METHODS: Fifty patients with recurrent or disseminated squamous cell carcinoma were included in the study. The treatment consisted of paclitaxel 175 mg/m(2) once every third week and capecitabine 825 mg/m(2) per oral (p.o.) twice daily (bid) for 2 weeks. RESULTS: The overall response rate according to the World Health Organization (WHO) criteria was 42%. Two patients had a complete response (CR), 19 patients had a partial response (PR), 14 patients had no change (NC), 12 patients had progressive disease (PD), and 3 patients were not evaluable (NE). The median survival time was 8 months. Toxicity was very moderate. Only 10% of 315 delivered treatments had to be given in reduced dose or postponed for a week or more. CONCLUSIONS: The toxicity was low and manageable. The overall response rate was comparable to the commonly used cisplatin/5-fluorouracil regimen.
BACKGROUND: The aim of this phase II study was to evaluate the antitumor activity and toxicity of a non-platin-containing regimen with paclitaxel and capecitabine. METHODS: Fifty patients with recurrent or disseminated squamous cell carcinoma were included in the study. The treatment consisted of paclitaxel 175 mg/m(2) once every third week and capecitabine 825 mg/m(2) per oral (p.o.) twice daily (bid) for 2 weeks. RESULTS: The overall response rate according to the World Health Organization (WHO) criteria was 42%. Two patients had a complete response (CR), 19 patients had a partial response (PR), 14 patients had no change (NC), 12 patients had progressive disease (PD), and 3 patients were not evaluable (NE). The median survival time was 8 months. Toxicity was very moderate. Only 10% of 315 delivered treatments had to be given in reduced dose or postponed for a week or more. CONCLUSIONS: The toxicity was low and manageable. The overall response rate was comparable to the commonly used cisplatin/5-fluorouracil regimen.
Authors: Elaine T Lam; Cindy L O'Bryant; Michele Basche; Daniel L Gustafson; Natalie Serkova; Anna Baron; Scott N Holden; Janet Dancey; S Gail Eckhardt; Lia Gore Journal: Mol Cancer Ther Date: 2008-12 Impact factor: 6.261
Authors: J Martinez-Trufero; D Isla; J C Adansa; A Irigoyen; R Hitt; I Gil-Arnaiz; J Lambea; M J Lecumberri; J J Cruz Journal: Br J Cancer Date: 2010-05-18 Impact factor: 7.640